Amarin Announces USPTO has Published Notification of Notice of Allowance for US Patent 13/610,247
Amarin (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/610,247. This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.
The '247 application is a continuation of Amarin's U.S. Patent Number 8,293,728 (formerly, the '153 application) and broadens the '728 claims by covering the use of Vascepa with and without other lipid lowering agents, such as statins. The '247 application claims gauge drug effects against a subject's own baseline and, alternatively, on a patient population basis. On November 19, 2012, Amarin announced notification of a Notice of Allowance for U.S. Patent Application Serial Number 13/608,775 which is also a continuation of the '728 application and also broadens the '728 claims by covering the use of Vascepa with and without other lipid lowering agents, but gauges Vascepa effects against placebo control.
A Notice of Allowance is